BioPharma Resources

Drug Trial Radar · NCT07482787

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jul 21, 2026

Primary completion

May 17, 2027

Study completion Jun 17, 2027

Sponsor

Lead sponsor
Paradigm TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 28 days, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry. There are only 4 site visits by patients with minimal assessments over a 2-month period, and patients completing this study will have the ability to continue receiving SD-101-6.0 at home in an open-label extension study. The drug product and placebo require no special preparation or storage conditions (room temperature).

Conditions

  • Epidermolysis Bullosa (EB)

Interventions

  • SD-101 Dermal Cream (6%)Drug

    SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.

  • Vehicle (SD-101 0%)Drug

    A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Target wound closureTime frame: 1 month

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Mission Dermatology

    Rancho Santa Margarita, California · Recruiting

  • Stanford University School of Medicine Dermatology Department

    Redwood City, California · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina Department of Dermatology and Dermatologic Surgery

    Charleston, South Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.